Get access

Exogenous L-lactate clearance in adult horses


  • All work was conducted at the University of Illinois Veterinary Medicine Teaching Hospital.

  • Dr. Wilkins is an assistant editor for the Journal but did not participate in the peer review process other than as an author.

  • The authors declare no other conflict of interest.

  • Presented in part at the American College of Veterinary Internal Medicine Forum in June 2010, Anaheim, CA.

Address correspondence and reprint requests to

Dr. Pamela A. Wilkins, DVM, PhD, DACVIM, DACVECC, Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, 1008 W. Hazelwood Drive, Urbana, IL 61802, USA. Email:



To determine endogenous production of L-lactate and the clearance of exogenous sodium L-lactate (ExLC) in healthy adult horses.


A sodium L-lactate solution (1 mmol/kg body weight qs to 500 mL final volume in 0.9% NaCl) was adminstered IV over 15 minutes. Blood samples for L-lactate concentration [LAC] measurement were collected immediately prior to infusion, at 5, 10, and 15 minutes during infusion and at 1 minute intervals for 15 minutes, at 30, 45, 60, 120, and 180 minutes postinfusion. Disposition modeling and pharmacokinetic analysis was performed using proprietary software.


University Teaching Hospital.


Six clinically healthy adult horses.

Measurements and Main Results

Median (range) baseline [LAC] was 0.43 (0.20–0.72) mmol/L for samples obtained every 3 hours over the 24 hours prior to ExLC and demonstrated variability primarily associated with horse. Median [LAC] immediately prior to ExLC was 0.43 (0.35–0.52) mmol/L. A 2-compartment model was used to specify the pharmacokinetic parameters. Median (range) ExLC was 1.05 (0.073–1.75) L·h−1·kg−1 and t1/2 β was 29.54 (20.8–38.6) min. Median lactate production based on basal [LAC] immediately prior to ExLC was was 0.49 (0.31–0.93) mmol·h−1·kg−1.


ExLC in healthy adult horses is greater than that of hyperlactemic human patients but similar to normolactemic-sick human patients examined using the same model, supporting development of species, and disease specific ExLC parameters.